It was also unexpected to find that receipt of more intensive, anthracycline-containing regimens varied by genetic results in HR-positive, HER2-negative disease, particularly given declining anthracycline use among US breast cancer patients overall in a MarketScan claims analysis (9); however, more platinum receipt was likely the primary driver of this result. Here, ERBB2 is linked to breast carcinoma.